Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, RaySearch Laboratories AB has a Sloan Ratio of -7.19%, indicating the company is in the safe zone and there is no funny business with accruals.
RaySearch Laboratories AB Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RaySearch Laboratories AB's Sloan Ratio %
For the Health Information Services subindustry, RaySearch Laboratories AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Sloan Ratio % falls into.
RaySearch Laboratories AB Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
RaySearch Laboratories AB's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
RaySearch Laboratories AB's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was 10.918 (Jun. 2023 ) + 21.551 (Sep. 2023 ) + 31.54 (Dec. 2023 ) + 36.698 (Mar. 2024 ) = kr101 Mil.
RaySearch Laboratories AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 67.214 (Jun. 2023 ) + 124.378 (Sep. 2023 ) + 115.772 (Dec. 2023 ) + 167.308 (Mar. 2024 ) = kr475 Mil.
RaySearch Laboratories AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -56.458 (Jun. 2023 ) + -43.673 (Sep. 2023 ) + -64.581 (Dec. 2023 ) + -60.809 (Mar. 2024 ) = kr-226 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (OSTO:RAY B) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, RaySearch Laboratories AB has a Sloan Ratio of -7.19%, indicating the company is in the safe zone and there is no funny business with accruals.
RaySearch Laboratories AB Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of RaySearch Laboratories AB's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
RaySearch Laboratories AB (OSTO:RAY B) Business Description
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia, Europe and the rest of the world. The company generates majority of its sales from the North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:RAY B has been successfully added to your 